Sodium Glucose Co-Transporter-2 (SGLT2) Inhibitors: A Review of Their Basic and Clinical Pharmacology
- PMID: 25424969
- PMCID: PMC4269649
- DOI: 10.1007/s13300-014-0089-4
Sodium Glucose Co-Transporter-2 (SGLT2) Inhibitors: A Review of Their Basic and Clinical Pharmacology
Erratum in
-
Erratum to: Sodium Glucose Co-Transporter-2 (SGLT2) Inhibitors: A Review of Their Basic and Clinical Pharmacology.Diabetes Ther. 2015 Mar;6(1):95. doi: 10.1007/s13300-015-0095-1. Epub 2015 Jan 15. Diabetes Ther. 2015. PMID: 25588327 Free PMC article. No abstract available.
Abstract
Sodium-glucose co-transporter-2 (SGLT2) inhibitors are a newly developed class of oral anti-diabetic drugs (OADs) with a unique mechanism of action. This review describes the biochemistry and physiology underlying the use of SGLT2 inhibitors, and their clinical pharmacology, including mechanism of action and posology. The pragmatic placement of these molecules in the existing OAD arena is also discussed.
References
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
